Human Th17 cells can be induced through head and neck cancer and have a functional impact on HNSCC development

British Journal of Cancer

Volumn 103, Issue 8, 2010, Pages 1245-1254

  Kesselring, R ^a   Thiel, A ^a   Pries, R ^a   Trenkle, T ^a   Wollenberg, B ^a  

^a UNIVERSITY OF LÜBECK   (Germany)

Author keywords

HNSCC; IL 17; Th17; tumour microenvironment; tumour infiltrating lymphocytes

Indexed keywords

ADULT; AGED; ANGIOGENESIS; ARTICLE; CARCINOGENESIS; CELL MIGRATION; CELL PROLIFERATION; CHEMOTAXIS; CLINICAL ARTICLE; FEMALE; FLOW CYTOMETRY; HEAD AND NECK CANCER; HELPER CELL; HUMAN; HUMAN CELL; MALE; PRIORITY JOURNAL; PROTEIN MICROARRAY; SQUAMOUS CELL CARCINOMA; BLOOD; CASE CONTROL STUDY; CELL MOTION; CELL TRANSFORMATION; CYTOLOGY; HEAD AND NECK TUMOR; IMMUNOLOGY; LEUKEMIC INFILTRATION; LYMPHOCYTE ACTIVATION; METABOLISM; MIDDLE AGED; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; PHYSIOLOGY; TH1 CELL; TUMOR ASSOCIATED LEUKOCYTE; TUMOR CELL LINE; VASCULARIZATION;

CYTOKINE;

AGED; CARCINOMA, SQUAMOUS CELL; CASE-CONTROL STUDIES; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; CYTOKINES; HEAD AND NECK NEOPLASMS; HUMANS; LEUKEMIC INFILTRATION; LYMPHOCYTE ACTIVATION; LYMPHOCYTES, TUMOR-INFILTRATING; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; TH1 CELLS;

EID: 77958003287     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6605891     Document Type: Article

References (52)

1. Acosta-Rodriguez EV, Napolitani G, Lanzavecchia A, Sallusto F (2007) Interleukins 1beta and 6 but not transforming growth factor-beta are essential for the differentiation of interleukin 17-producing human T helper cells. Nat Immunol 8: 942-949
2. Agarwal S, Misra R, Aggarwal A (2008) Interleukin 17 levels are increased in juvenile idiopathic arthritis synovial fluid and induce synovial fibroblasts to produce proinflammatory cytokines and matrix metallo-proteinases. J Rheumatol 35: 515-519
3. Benchetrit F, Ciree A, Vives V, Warnier G, Gey A, Sautes-Fridman C, Fossiez F, Haicheur N, Fridman WH, Tartour E (2002) Interleukin-17 inhibits tumor cell growth by means of a T-cell-dependent mechanism. Blood 99: 2114-2121
4. Bose A, Chakraborty T, Chakraborty K, Pal S, Baral R (2008) Dysregulation in immune functions is reflected in tumor cell cytotoxicity by peripheral blood mononuclear cells from head and neck squamous cell carcinoma patients. Cancer Immun 8: 10
5. Braakhuis BJ, Leemans CR, Brakenhoff RH (2005) Expanding fields of genetically altered cells in head and neck squamous carcinogenesis. Semin Cancer Biol 15: 113-120
6. Brennan PA, Palacios-Callender M, Zaki GA, Spedding AV, Langdon JD (2001) Type II nitric oxide synthase (NOS2) expression correlates with lymph node status in oral squamous cell carcinoma. J Oral Pathol Med 30: 129-134 (Pubitemid 32139982)
7. Bronte V (2008) Th17 and cancer: friends or foes? Blood 112: 214
8. Camacho M, Leon X, Fernandez-Figueras MT, Quer M, Vila L (2008) Prostaglandin E(2) pathway in head and neck squamous cell carcinoma. Head Neck 30: 1175-1181
9. Castermans K, Tabruyn SP, Zeng R, van Beijnum JR, Eppolito C, Leonard WJ, Shrikant PA, Griffioen AW (2008) Angiostatic activity of the antitumor cytokine interleukin-21. Blood 112: 4940-4947
10. Chin D, Boyle GM, Theile DR, Parsons PG, Coman WB (2004) Molecular introduction to head and neck cancer (HNSCC) carcinogenesis. Br J Plast Surg 57: 595-602
11. Chizzolini C, Chicheportiche R, Alvarez M, de Rham C, Roux-Lombard P, Ferrari-Lacraz S, Dayer JM (2008) Prostaglandin E2 synergistically with interleukin-23 favors human Th17 expansion. Blood 112: 3696-3703
12. Ciree A, Michel L, Camilleri-Broet S, Jean Louis F, Oster M, Flageul B, Senet P, Fossiez F, Fridman WH, Bachelez H, Tartour E (2004) Expression and activity of IL-17 in cutaneous T-cell lymphomas (mycosis fungoides and Sezary syndrome). Int J Cancer 112: 113-120
13. Coquet JM, Chakravarti S, Kyparissoudis K, McNab FW, Pitt LA, McKenzie BS, Berzins SP, Smyth MJ, Godfrey DI (2008) Diverse cytokine production by NKT cell subsets and identification of an IL-17-producing CD4-NK1.1-NKT cell population. Proc Natl Acad Sci USA 105: 11287-11292
14. Cosmi L, De Palma R, Santarlasci V, Maggi L, Capone M, Frosali F, Rodolico G, Querci V, Abbate G, Angeli R, Berrino L, Fambrini M, Caproni M, Tonelli F, Lazzeri E, Parronchi P, Liotta F, Maggi E, Romagnani S, Annunziato F (2008) Human interleukin 17-producing cells originate from a CD161+CD4+ T cell precursor. J Exp Med 205: 1903-1916
15. Diveu C, McGeachy MJ, Boniface K, Stumhofer JS, Sathe M, Joyce-Shaikh B, Chen Y, Tato CM, McClanahan TK, de Waal Malefyt R, Hunter CA, Cua DJ, Kastelein RA (2009) IL-27 blocks RORc expression to inhibit lineage commitment of Th17 cells. J Immunol 182: 5748-5756
16. Douglas WG, Tracy E, Tan D, Yu J, Hicks Jr WL, Rigual NR, Loree TR, Wang Y, Baumann H (2004) Development of head and neck squamous cell carcinoma is associated with altered cytokine responsiveness. Mol Cancer Res 2: 585-593
17. Garcia-Hernandez Mde L, Hamada H, Reome JB, Misra SK, Tighe MP, Dutton RW (2010) Adoptive transfer of tumor-specific Tc17 effector T cells controls the growth of B16 melanoma in mice. J Immunol 184: 4215-4227
18. Gu Y, Hu X, Liu C, Qv X, Xu C (2008) Interleukin (IL)-17 promotes macrophages to produce IL-8, IL-6 and tumour necrosis factor-alpha in aplastic anaemia. Br J Haematol 142: 109-114
19. Harrington LE, Hatton RD, Mangan PR, Turner H, Murphy TL, Murphy KM, Weaver CT (2005) Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol 6: 1123-1132
20. Honorati MC, Neri S, Cattini L, Facchini A (2003) IL-17 enhances the susceptibility of U-2 OS osteosarcoma cells to NK cell lysis. Clin Exp Immunol 133: 344-349
21. Ivanov II, McKenzie BS, Zhou L, Tadokoro CE, Lepelley A, Lafaille JJ, Cua DJ, Littman DR (2006) The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17+ T helper cells. Cell 126: 1121-1133
22. Kim-Schulze S, Kim HS, Fan Q, Kim DW, Kaufman HL (2009) Local IL-21 promotes the therapeutic activity of effector T cells by decreasing regulatory T cells within the tumor microenvironment. Mol Ther 17: 380-388
23. Kondo T, Takata H, Matsuki F, Takiguchi M (2009) Cutting edge: phenotypic characterization and differentiation of human CD8+ T cells producing IL-17. J Immunol 182: 1794-1798
24. Kryczek I, Wei S, Szeliga W, Vatan L, Zou W (2009) Endogenous IL-17 contributes to reduced tumor growth and metastasis. Blood 114: 357-359
25. Lamprecht B, Kreher S, Anagnostopoulos I, Johrens K, Monteleone G, Jundt F, Stein H, Janz M, Dorken B, Mathas S (2008) Aberrant expression of the Th2 cytokine IL-21 in Hodgkin lymphoma cells regulates STAT3 signaling and attracts Treg cells via regulation of MIP-3alpha. Blood 112: 3339-3347
26. Lee KA, Kang MH, Lee YS, Kim YJ, Kim DH, Ko HJ, Kang CY (2008) A distinct subset of natural killer T cells produces IL-17, contributing to airway infiltration of neutrophils but not to airway hyperreactivity. Cell Immunol 251: 50-55
27. Li A, Dubey S, Varney ML, Dave BJ, Singh RK (2003) IL-8 directly enhanced endothelial cell survival, proliferation, and matrix metalloproteinases production and regulated angiogenesis. J Immunol 170: 3369-3376
28. Liu Z, Yang L, Cui Y, Wang X, Guo C, Huang Z, Kan Q, Liu Y (2009) Il-21 enhances NK cell activation and cytolytic activity and induces Th17 cell differentiation in inflammatory bowel disease. Inflamm Bowel Dis 15: 1133-1144
29. Martinez GJ, Nurieva RI, Yang XO, Dong C (2008) Regulation and function of proinflammatory TH17 cells. Ann NY Acad Sci 1143: 188-211
30. Menoret E, Maiga S, Descamps G, Pellat-Deceunynck C, Fraslon C, Cappellano M, Moreau P, Bataille R, Amiot M (2008) IL-21 stimulates human myeloma cell growth through an autocrine IGF-1 loop. J Immunol 181: 6837-6842
31. Miyahara Y, Odunsi K, Chen W, Peng G, Matsuzaki J, Wang RF (2008) Generation and regulation of human CD4+ IL-17-producing T cells in ovarian cancer. Proc Natl Acad Sci USA 105: 15505-15510
32. Muranski P, Boni A, Antony PA, Cassard L, Irvine KR, Kaiser A, Paulos CM, Palmer DC, Touloukian CE, Ptak K, Gattinoni L, Wrzesinski C, Hinrichs CS, Kerstann KW, Feigenbaum L, Chan CC, Restifo NP (2008) Tumor-specific Th17-polarized cells eradicate large established melanoma. Blood 112: 362-373
33. Nabeshima K, Inoue T, Shimao Y, Sameshima T (2002) Matrix metallo-proteinases in tumor invasion: role for cell migration. Pathol Int 52: 255-264
34. Nam JS, Terabe M, Kang MJ, Chae H, Voong N, Yang YA, Laurence A, Michalowska A, Mamura M, Lonning S, Berzofsky JA, Wakefield LM (2008) Transforming growth factor beta subverts the immune system into directly promoting tumor growth through interleukin-17. Cancer Res 68: 3915-3923
35. Napolitani G, Acosta-Rodriguez EV, Lanzavecchia A, Sallusto F (2009) Prostaglandin E2 enhances Th17 responses via modulation of IL-17 and IFN-gamma production by memory CD4(+) T cells. Eur J Immunol 39: 1301-1312
36. Numasaki M, Watanabe M, Suzuki T, Takahashi H, Nakamura A, McAllister F, Hishinuma T, Goto J, Lotze MT, Kolls JK, Sasaki H (2005) IL-17 enhances the net angiogenic activity and in vivo growth of human non-small cell lung cancer in SCID mice through promoting CXCR-2-dependent angiogenesis. J Immunol 175: 6177-6189
37. O'Brien RL, Roark CL, Born WK (2009) IL-17-producing gammadelta T cells. Eur J Immunol 39: 662-666
38. Pries R, Wollenberg B (2006) Cytokines in head and neck cancer. Cytokine Growth Factor Rev 17: 141-146
39. Rachitskaya AV, Hansen AM, Horai R, Li Z, Villasmil R, Luger D, Nussenblatt RB, Caspi RR (2008) Cutting edge: NKT cells constitutively express IL-23 receptor and RORgammat and rapidly produce IL-17 upon receptor ligation in an IL-6-independent fashion. J Immunol 180: 5167-5171
40. Roark CL, Simonian PL, Fontenot AP, Born WK, O'Brien RL (2008) gammadelta T cells: an important source of IL-17. Curr Opin Immunol 20: 353-357
41. Romagnani S, Maggi E, Liotta F, Cosmi L, Annunziato F (2009) Properties and origin of human Th17 cells. Mol Immunol 47: 3-7
42. Rubie C, Frick VO, Wagner M, Rau B, Weber C, Kruse B, Kempf K, Tilton B, Konig J, Schilling M (2006a) Enhanced expression and clinical significance of CC-chemokine MIP-3 alpha in hepatocellular carcinoma. Scand J Immunol 63: 468-477
43. Rubie C, Oliveira V, Kempf K, Wagner M, Tilton B, Rau B, Kruse B, Konig J, Schilling M (2006b) Involvement of chemokine receptor CCR6 in colorectal cancer metastasis. Tumour Biol 27: 166-174
44. Singh SP, Zhang HH, Foley JF, Hedrick MN, Farber JM (2008) Human T cells that are able to produce IL-17 express the chemokine receptor CCR6. J Immunol 180: 214-221
45. Smyth MJ, Teng MW, Sharkey J, Westwood JA, Haynes NM, Yagita H, Takeda K, Sivakumar PV, Kershaw MH (2008) Interleukin 21 enhances antibody-mediated tumor rejection. Cancer Res 68: 3019-3025
46. Su X, Ye J, Hsueh EC, Zhang Y, Hoft DF, Peng G (2010) Tumor microenvironments direct the recruitment and expansion of human Th17 cells. J Immunol 184: 1630-1641
47. Uppaluri R, Dunn GP, Lewis Jr JS (2008) Focus on TILs: prognostic significance of tumor infiltrating lymphocytes in head and neck cancers. Cancer Immun 8: 16
48. Weber GF, Gaertner FC, Erl W, Janssen KP, Blechert B, Holzmann B, Weighardt H, Essler M (2006) IL-22-mediated tumor growth reduction correlates with inhibition of ERK1/2 and AKT phosphorylation and induction of cell cycle arrest in the G2-M phase. J Immunol 177: 8266-8272
49. Wei LH, Kuo ML, Chen CA, Chou CH, Lai KB, Lee CN, Hsieh CY (2003) Interleukin-6 promotes cervical tumor growth by VEGF-dependent angiogenesis via a STAT3 pathway. Oncogene 22: 1517-1527
50. Yamazaki T, Yang XO, Chung Y, Fukunaga A, Nurieva R, Pappu B, Martin-Orozco N, Kang HS, Ma L, Panopoulos AD, Craig S, Watowich SS, Jetten AM, Tian Q, Dong C (2008) CCR6 regulates the migration of inflammatory and regulatory T cells. J Immunol 181: 8391-8401
51. Zhang B, Rong G, Wei H, Zhang M, Bi J, Ma L, Xue X, Wei G, Liu X, Fang G (2008a) The prevalence of Th17 cells in patients with gastric cancer. Biochem Biophys Res Commun 374: 533-537
52. Zhang W, Chen Y, Wei H, Zheng C, Sun R, Zhang J, Tian Z (2008b) Antiapoptotic activity of autocrine interleukin-22 and therapeutic effects of interleukin-22-small interfering RNA on human lung cancer xenografts. Clin Cancer Res 14: 6432-6439